CDKN2A and central nervous system neoplasm: Although TERT promoter mutations and CDKN2A/B deletions are known to confer WHO grade III meningiomas in the latest WHO grades for CNS tumours, we did not evaluate the respective molecular analyses (TERT promoter and CDKN2A/B deletion) and utilised the 2016 WHO classifications.